Replies to post #13536 on Tao Synergies Inc (TAOX)

[runncoach]

Nice preclinical work similar to what the other sigma 1 failures had. I've given links several times to both pre clincal and the failed P2 studies. M1 study abandoned for cognition failure already as well.
Pridopidine study. Sounds good pre clinic. https://www.ncbi.nlm.nih.gov/pubmed/30756361

Not so good in the clinic. From January article.
https://huntingtonsdiseasenews.com/2019/01/03/huntexil-fails-to-improve-motor-function-of-huntingtons-patients-in-phase-2-trial/

Toyama's Sigma1 drug, T-817MA AD.
Looked great pre clinical.
https://www.fujifilmholdings.com/en/news/2014/0609_01_01.html

Failed in the clinic.
https://www.genengnews.com/news/fujifilms-alzheimers-candidate-fails-phase-ii-trial/

M1 AD trial last year. Abandoned.
https://www.sciencedirect.com/science/article/pii/S235287371830012X
Plenty of things work well in preclinical studies and plenty of drugs claim autophagy or degrees of homeostasis. Even things other than drugs claim to promote autophagy including fasting.

What I haven't heard is a reason that restoring normal endogenous brain enzyme levels, therefore regrowing the synpatic network would NOT result in successful AD trials. This is no longer preclinical in nature or a hypothesis paper. Its in human trials.

https://neurotrope.com/wp-content/uploads/2018/12/JAD180759.pdf